BridgeBio Pharma seeks a Skeletal Dysplasia Account Manager to drive the launch of Infigratinib for achondroplasia. This remote role targets the Central USA region with complex clinical and payer engagement, delivering strategic plans and outcomes.
You will collaborate with cross-functional teams, expand KOL networks, and ensure compliant, data-driven execution across providers and families.
#J-18808-Ljbffr